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FLUCONAZOLE THERAPY IN TRANSPLANT RECIPIENTS RECEIVING FK5061 
Fungal infections remain an important cause of morbidity 
and mortality following solid organ and bone marrow trans-
plantation (1-3). Use of amphotericin B, the antifungal agent 
of choice at present, is frequently associated with a high 
incidence of side effects. In organ transplant patients par-
ticularly, the nephrotoxicity of amphotericin may be ampli-
fied when combined with immunosuppressive agents such 
cyclosporine or FK506. 
F1uconazole, a new antifungal agent with low toxicity and 
excellent oral bioavailability has been shown to be effective in 
both the treatment and prophylaxis of fungal infections in 
immunocompromised patients (4, 5). However, fluconazole is 
known to inhibit the cytochrome P-450 enzyme system in 
humans and animals. Coadministration of fluconazole with 
cyclosporine, a drug that is primarily metabolized in the 
liver, results in increased cyclosporine blood concentrations 
in transplant patients (6). Since FK506 is also known to be 
primarily eliminated by hepatic metabolism, coadministra-
tion of fluconazole to patients on FK506 therapy is expected 
to increase FK506 concentrations in patients (7). In rats, 
fluconazole is known to increase FK506 blood concentrations 
(8). In this communication we report our observations on the 
interaction between FK506 and fluconazole in transplant 
patients. 
Twenty organ transplant patients under FK506 immuno-
suppression were evaluated while receiving a course of flu-
conazole therapy. The patient population included 11 pa-
tients who received livers (OLTX); 6 patients who received 
kidneys (KTX1. 2 patients who received hearts (HTXl and one 
bone marrow patient. The immunosuppressive regimen in-
cluded FK506 and low-dose steroids (20 mg/day). FK506 was 
given initially as a continuous i.v. infusion at 0.1 mglkg/day, 
with conversion to the oral dose of 0.15 mglkg every 12 hr 
with the return of normal bowel function. Subsequent dose 
adjustments were guided by the quality of the graft. the 
presence of any evidence of rejection. signs of toxicity, and 
trough FK506 plasma concentrations (normal range 0.5 to 2 
ng/mll. 
Sixteen of the patients studied had documented fungal 
infection (7 urinary tract infections. 4 esophagitis. 2 pyelone-
phritis. 2 tracheobronchitis. and 1 cholangitis 1. Candida al-
bicans was the most common pathogen isolated (14 patients). 
whereas Candida tropicalis and Cryptococcus neo(ormans 
were isolated in one patient each. Four additional patients 
were considered high-risk patients and were treated with 
prophviactlc fluconazole. The median time from transplanta-
tIOn t[) the illltiatlOn of f1uconazole therapy was 60 days 
I range 2-1680 days). In patients with documented fungal 
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infection, fluconazole was given for a median of 14 days 
(range 7-100 days). Fourteen of the 16 patients were success-
fully treated and became culture-negative. Two failures were 
noted in two kidney transplant patients who required trans-
plant nephrectomy for persistent fungal invasion of the graft. 
Four patients received prophylactic fluconazole for a median 
of 12 days (range 6-a0 days), and all remained fungal culture 
negative. F1uconazole was used at a dose of 200 mg/day in 8 
patients and 100 mg/day in 12 patients. FK506 plasma con-
centrations were measured by an ELISA (9). The intraday 
coefficient of variation for this assay ranged from 4.2 to 5.5% 
and the interday coefficient of variation ranged from 14.4 to 
17% at concentrations measured in this study. Figure 1 
shows the median plasma trough concentration of FK506 on 
days -1, 0, 1, 2, 3, 4, 5, and 7 after fluconazole therapy as a 
function of the fluconazole dose administered. On day 1, the 
median plasma trough concentration ofFK506 increased 1.4· 
fold in patients receiving 100 mg/day of fluconazole and 3.1-
fold in patients receiving 200 mg/day. Thereafter the FK506 
plasma concentration decreased as the FK506 dose was re-
duced to prevent higher FK506 concentrations. Figure 2 
shows the median dose of FK506 and the plasma concentra-
tion ofFK506 on days -1, 0,1,2,3,4,5, and 7 of fluconazole 
therapy. A median FK506 dose reduction of 56% (range 0% to 
88%) was required in order to maintain the FK506 concen-
trations below 2 ng/ml. There was no change in the route of 
FK506 administration during the period studied. The initial 
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FIGURE 1. :'vledian plasma trough concentration of FK506 in pa-
tients receiving 100 mg (continuous line) and 200 mg (interrupted 
line) of fluconazole, 
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FIGURE 2. Median dose (mg/day) (continuous line) and plasma 
trough concentration (ng/ml) (interrupted line) ofFK506 during flu-
conazole therapy. 
increase in FK506 plasma concentration during fluconazole 
therapy was associated with acute renal dysfunction in 3 
patients (hemodialysis required in one) and acute changes in 
the mental status in 2 patients. 
The pharmacokinetics of FK506 was evaluated in one pa-
tient on two occasions, once while on fluconazole therapy (100 
mg oral dose, 1 hr prior to FK506 dosing of 3 mg) and again 
eight days after stopping fluconazole therapy. Figure 3 shows 
FK506 the plasma concentration vs. time profile over a dos-
ing interval in this patient with and without fluconazole 
therapy. Discontinuation of fluconazole therapy resulted in 
a significant decrease in the area under the plasma 
concentration-versus-time curve ofFK506 (from 13 ng/mllhr 
to 5.4 ng/mllhrl. The half-life maximum plasma concentra-
tion and the trough plasma concentration of FK506 also de· 
creased during this period. 
FK506 level (ng/ml) 
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FIGCRE J. FK506 pharmacokinetlc protile or one patient with (con-
tinUOUS line, and Wlthout (Interrupted line, tluconazole therapy. 
FK506 is a new immunosuppressive drug with a proven 
beneficial effect over currently available agents (10-12). Its 
elimination through hepatic metabolism by cytochrome 
P-450 enzyme makes it susceptible to possible interactions 
with other drugs as that are known to induce or inhibit these 
enzymes, such as phenobarbital, phenytoin, rifampin, clo-
trimazole, ketoconazole, itraconazole, fluconazole, cimeti-
dine, and erythromycin (7). In rats, FK506 blood concentra-
tions are reported to increase in the presence of fluconazole, 
erythromycin, ketoconazole, and diltiazam (8). Erythromycin 
and methylprednisolone have been reported to increase 
FK506 plasma concentrations (7). Clotrimazole treatment 
also increases FK506 plasma concentrations in liver trans-
plant patients (13). The data reported here show an increase 
in trough and maximal plasma concentration ofFK506, along 
with an increase in the half-life of FK506 in the presence of 
fluconazole. This suggests that fluconazole inhibits FK506 
metabolism. It is not possible to predict whether fluconazole 
decreases FK506 metabolism in the gut and therefore in-
creases the extent of absorption or whether it affects only the 
hepatic metabolism of FK506. Additional studies are re-
quired to understand the extent to which this interaction 
takes place in the small bowel and/or the liver. The increases 
in the plasma concentration of FK506 were higher at a 200 
mg/day fluconazole dose than at a 100 mg/day dose. This 
dose-related effect, also reported with CsA (6), may have 
important implications when fluconazole is used in the treat-
ment of severe fungal infections. Recently, a new fluconazole 
dosing regimen (200-400 mg/day) has been suggested for the 
treatment of invasive candidiasis (14). FK506 concentrations 
should be carefully monitored when using these dosing regi-
mens. Despite the similarities between fluconazole's interac-
tion with CsA and FK506, some differences were observed. In 
renal transplant recipients, fluconazole slowly increased cy-
closporine trough concentrations over a two-week period. 
reaching a maximum of twice the baseline level (6). In our 
patients the highest concentration of FK506 was seen within 
three days after the introduction of fluconazole therapy. 
In summary, fluconazole therapy in patients under FK506 
immunosuppression appears to be beneficial for both prophy-
laxis and treatment offungal infections. Fluconazole doses of 
up to 200 mg/day can be safely and effectively administered 
to transplant patients on FK506 therapy provided that the 
FK506 dose is reduced by half. Use of higher doses offlucon-
azole would require careful monitoring of trough FK506 
plasma concentrations and corresponding reduction in 
FK506 doses to avoid nephrotoxicity. 
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POSTTRANSPLANT BLADDER RECOVERY -A PROSPECTIVE RANDOMIZED TRIAL OF TWO TECHNIQUES 
OF URETERIC ANASTOMOSIS 
There is good evidence that vesical function deteriorates 
significantly while patients with end-stage renal failure are 
on dialysis (1-3) but the extent of its recovery posttrans-
plantation is not clear. Prat et a1. (4) reported on bladder 
evacuating capacity after renal transplantation and found it 
to be impaired, especially in the presence of a urinary tract 
infection. The impairment could not be related to age, the 
volume of urine passed prior to transplantation. or the 
length of the postoperative period. They attributed the dis-
turbed bladder evacuating ability to the degree of bladder 
wall injury sustained on ureteral implantation, with subse-
quent predisposition to recurrent urinary tract infection. 
This study investigates the extent of recovery of the bladder 
function posttransplantation and whether the less-
traumatic technique of extravesical ureteroneocystostomy 
allows greater improvement than the intravesical tunneled 
ureteric implantation. 
This prospective randomized study allocated 48 patients to 
either intravesical <Int) or extra vesical (Ext)* ureteroneocys-
tostomy lUNC) following an initial preoperative urodynamic 
study and clinical examination (5). Patients with a previous 
history of a surgical operation on the urinary bladder and 
those With a vesical capacity of less than 150 ml were ex-
cluded. Randomization was carried out by using a statistical 
package lEpistat. Round Rock, TX) to produce a numerical 
sequence for allocation of patients to either arm of the study. 
usmg sealed blank envelopes opened following revasculariza-
tion of the kidney. 
Immediately pnor to surgery all patients completed two 
• AbbreVlations: Ext. extravesical: Int. intravesical: UNe. ure-
teroneocystostomy. 
detailed urological questionnaires at the time of the initial 
study (one surveying the pre-renal failure stage and the 
other the pretransplant period) that provided information on 
vesical function (such as frequency of micturition, nocturia, 
quality of flow, and hesitancy). 
The internal ureteroneocystostomy (int. UNC) involved re-
flecting the peritoneum off the posterolateral aspect of the 
bladder, after which a 4-5-cm midline cystotomy was made. 
A 1-2-cm submucosal tunnel was then created, and, after 
marking the superior aspect of the ureter with a suture, it 
was pulled through into the tunnel. The ureter was anasto-
mosed to the vesical mucosa, using interrupted 3/0 plain 
catgut in such a way as to produce a nipple at the junction. 
The cystotomy was closed in two layers using 210 catgut and 
Surgilon (braided nylon). 
The external ureteroneocystostomy (ext. UNC) comprised 
the creation of a small1-cm cystotomy and direct anastomo-
sis of the ureter to the edge of the bladder mucosa using 
interrupted 3/0 plain catgut sutures. A short (1-cm) extravesi-
cal tunnel was then created by suturing the perivesical tissue 
over the distal ureter and the anastomosis. 
At 3 months posttransplant the patients completed a fur-
ther questionnaire and also underwent a repeat urodynamic 
study of the bladder. Follow-up data on graft function has 
been obtained for up to 2 years. 
Only patients with full data are included in the final evalu-
ation. The Mann-Whitney U test was used for statistical 
analysis of the data. 
A total of 39 completed studies (19 ext. UNC; 20 into UNC) 
are available for full analysis because the randomized proce-
dure was not carried out in one patient, one recipient with-
drew immediately after the pretransplant study and random-
